March 3, 2026Open Access

ICAM2 loss drives 5-fluorouracil resistance via TGF-β/Smad/SP1/PTN-dependent apoptosis evasion and macrophage remodeling in gastric cancer

Key Points

Downregulation of icam2 predicts poor outcomes in gastric cancer patients, highlighting its clinical significance.
The study indicates a specific signaling pathway, icam2/tgf-β/smad/sp1/ptn, mediates chemotherapy resistance.
Observational analysis reveals macrophage remodeling linked to icam2 loss contributes to apoptosis evasion in cancer cells.
Findings suggest targeting icam2 could enhance treatment effectiveness by overcoming 5-FU resistance.

Abstract

Our study highlights the clinical impact of ICAM2 downregulation predicting poor outcome and NACT response in AGC patients, and reveals a novel ICAM2/TGF-β/Smad/SP1/PTN signaling mediating 5-FU resistance in GC.

ICAM2 loss drives 5-fluorouracil resistance via TGF-β/Smad/SP1/PTN-dependent apoptosis evasion and macrophage remodeling in gastric cancer

Key Points

Abstract

Cite This Study